I get the feeling NTI doesn't agree with you re orphan drug status. You have mentioned before that getting FDA approval is a very long process. Attaining orphan drug status helps to fast track that process as far as I am aware? So, I would think attaining that status should be a positive and give some sort or appreciation to the shareprice, how much that is, I'm not sure.
I guess with Fenix, NTI thought this way forward with them is a best outcome for the company...otherwise, why would they be doing it? If Fenix hit those targets then, the company is moving fwd and the shareprice should be up....
Ann: Strategic Partnership with Fenix Innovation Group, page-9
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
-0.002(2.63%) |
Mkt cap ! $75.28M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.4¢ | $309.2K | 4.073M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45202 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.31pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
-0.002 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.7¢ | 7.4¢ | 135838 | ||
| Last updated 15.09pm 24/05/2024 ? | |||||
| NTI (ASX) Chart |